Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies

Vandana Singh
1 min read
0
In this article:

Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity in models of breast, lung, and ovarian cancer, including in a PARP inhibitor-resistant model.

  • The data support the advancement of a development candidate from Syros' CDK12 inhibitor program towards clinical development.

  • As a single agent in cancer cell models, the CDK12 inhibitor induced DNA damage, cell cycle dysregulation, and genomic instability leading to growth inhibition and apoptosis.

  • Additionally, as a single agent in in vivo cancer models, the Company's CDK12 inhibitor demonstrated tumor regressions in small cell lung cancer and breast cancer models at well-tolerated doses.

  • Related: Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings.

  • In combination in vitro, the CDK12 inhibitor exhibited synergistic or additive antiproliferative effects with lurbinectedin and olaparib, with increases in DNA damage and impaired DNA damage repair.

  • Lurbinectedin is marketed by Jazz Pharmaceutical Inc (NASDAQ: JAZZ) as Zepzelca and AstraZeneca Plc (NASDAQ: AZN) - Merck & Co Inc's (NYSE: MRK) market olaparib under Lynparza name.

  • Price Action: SYRS shares are down 7.83% at $1.06 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories